Search results for Cusatuzumab

Cusatuzumab Biosimilar – Anti-CD70, TNFSF7 mAb – Research Grade, ProteoGenix, PX-TA1500

Description of Cusatuzumab Biosimilar - Anti-CD70, TNFSF7 mAb - Research Grade Cusatuzumab Biosimilar: An Anti-CD70, TNFSF7 mAb for Targeted Therapy Cusatuzumab Biosimilar, also known as anti-CD70 or TNFSF7 monoclonal antibody, is a research grade biologic drug that has shown promising results in the treatment of various cancers. This biosimilar is a replica of the original drug, Cusatuzumab, which was developed by the pharmaceutical company Novartis. The biosimilar version is being developed by various companies for its potential use as a more affordable and accessible alternative for patients. Structure of Cusatuzumab Biosimilar Cusatuzumab Biosimilar is a monoclonal antibody that specifically targets CD70, a protein found on the surface of cancer cells. It is a humanized IgG1 kappa antibody, meaning it is made up of human and mouse components to reduce the risk of immune reactions. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy and two light chains, connected by disulfide bonds. The binding site of Cusatuzumab Biosimilar is located on the variable region of the heavy chain, which allows it to bind to CD70 with high specificity and affinity. This binding triggers a series of immune responses that ultimately lead to the destruction of cancer cells. Mechanism of Action The main therapeutic target of Cusatuzumab Biosimilar is CD70, a protein that is overexpressed in many types of cancer, including solid tumors and hematologic malignancies. CD70 is a member of the tumor necrosis factor (TNF) superfamily and plays a crucial role in the proliferation and survival of cancer cells. When Cusatuzumab Biosimilar binds to CD70, it blocks its interaction with its receptor, CD27, which is expressed on the surface of immune cells. This prevents the activation of the CD70-CD27 pathway, which is responsible for promoting cancer cell growth and survival. In addition, the binding of Cusatuzumab Biosimilar to CD70 also triggers the immune system to recognize and attack cancer cells, further enhancing its anti-tumor activity. Applications of Cusatuzumab Biosimilar The primary application of Cusatuzumab Biosimilar is in the treatment of cancer. It has shown promising results in preclinical and clinical studies for various types of cancer, including acute myeloid leukemia, multiple myeloma, and solid tumors such as renal cell carcinoma and non-small cell lung cancer. In addition to its use as a monotherapy, Cusatuzumab Biosimilar has also been studied in combination with other anti- cancer drugs, such as chemotherapy and immune checkpoint inhibitors. These combination therapies have shown synergistic effects and have the potential to further improve treatment outcomes for cancer patients. Conclusion Cusatuzumab Biosimilar is a promising biologic drug with a unique mechanism of action that specifically targets CD70, a protein involved in the growth and survival of cancer cells. Its potential as a more affordable and accessible alternative to the original drug makes it an attractive option for cancer treatment. With ongoing research and clinical trials, Cusatuzumab Biosimilar has the potential to become a valuable addition to the arsenal of anti- cancer therapies. Keywords: Cusatuzumab Biosimilar, anti-CD70, TNFSF7 mAb, monoclonal antibody, cancer, therapeutic target

Cusatuzumab, Kyinno, KB-1174

Cusatuzumab, Abbexa, abx831459

Cusatuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD70/TNFSF7, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Cusatuzumab is an experimental SIMPLE antibody that targets CD70, which is an immune checkpoint target involving hematological malignancies, a variety of solid tumors, and a variety of autoimmune diseases. Cusatuzumab aims to block CD70 by targeting complement-dependent cytotoxicity, enhancing antibody-dependent cell-mediated phagocytosis, and enhancing antibody-dependent cell-mediated cytotoxicity, killing CD70-expressing cancer cells, and recovering Immune monitoring of solid tumors.

Cusatuzumab ELISA Kit, ProteoGenix, KPTX221

Description of Cusatuzumab ELISA Kit The Structure of Cusatuzumab ELISA Kit Cusatuzumab ELISA Kit is a highly specific and sensitive enzyme-linked immunosorbent assay (ELISA) kit designed for the detection and quantification of Cusatuzumab in biological samples. Cusatuzumab, also known as ARGX-110, is a humanized monoclonal antibody that targets the CD70 protein, which is overexpressed in various types of cancer cells. The Cusatuzumab ELISA Kit is composed of several components, including microtiter plates coated with a specific anti-Cusatuzumab antibody, a detection antibody conjugated with an enzyme, and a substrate solution. The microtiter plate is pre-coated with the anti-Cusatuzumab antibody, which specifically binds to Cusatuzumab present in the sample. The detection antibody, which is conjugated with an enzyme, binds to the captured Cusatuzumab, forming a sandwich complex. The enzyme converts the substrate solution into a detectable signal, which is then measured using a spectrophotometer. The Activity of Cusatuzumab ELISA Kit The Cusatuzumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Cusatuzumab in biological samples. The kit has a limit of detection (LOD) of 0.1 ng/mL, making it suitable for detecting low levels of Cusatuzumab in patient samples. The assay has a wide dynamic range of 0.2-10 ng/mL, allowing for the accurate measurement of Cusatuzumab concentrations in both high and low levels. The activity of the Cusatuzumab ELISA Kit is based on the principle of sandwich ELISA, which is a widely used technique for the quantification of specific proteins in biological samples. The kit utilizes a highly specific anti-Cusatuzumab antibody for capturing Cusatuzumab in the sample, and a detection antibody conjugated with an enzyme for signal amplification. This results in a highly sensitive and specific assay for the detection of Cusatuzumab. The Application of Cusatuzumab ELISA Kit Cusatuzumab ELISA Kit has various applications in the field of cancer research and drug development. The kit can be used to measure the levels of Cusatuzumab in patient samples, providing valuable information for the monitoring of Cusatuzumab therapy. It can also be used to assess the pharmacokinetics and pharmacodynamics of Cusatuzumab, which are essential for understanding its efficacy and safety in clinical trials. Moreover, the Cusatuzumab ELISA Kit can also be used for the screening of potential therapeutic targets for Cusatuzumab in various cancer types. As CD70 is overexpressed in many cancers, this ELISA kit can aid in the identification of CD70-positive tumors, which can potentially benefit from Cusatuzumab therapy. In addition, the Cusatuzumab ELISA Kit can also be used in the development and quality control of Cusatuzumab-based therapeutics. The accurate quantification of Cusatuzumab levels in different formulations and batches is crucial for ensuring the consistency and efficacy of the drug. Conclusion In summary, the Cusatuzumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Cusatuzumab in biological samples. Its unique structure and activity make it a valuable tool for cancer research and drug development, with various applications in the monitoring of Cusatuzumab therapy, identification of potential therapeutic targets, and quality control of Cusatuzumab-based therapeutics.

Cusatuzumab ELISA Kit, Abbexa, abx395110

Cusatuzumab ELISA Kit is a quantitative ELISA kit for detection of Cusatuzumab.Cusatuzumab is designed as a first-in-class, high-affinity anti-CD70 monoclonal antibody with multiple intended mechanisms of action, including Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in killing of malignant cells such as leukemia blasts and stem cells.

Cusatuzumab Biosimilar - Research Grade, ichor.bio, ICH5037

Detects human CD70. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Cusatuzumab.

Research Grade Cusatuzumab (HW717016), abinScience, HW717016